Captrust Financial Advisors bought a new position in shares of Zoetis Inc (NYSE:ZTS) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,648 shares of the company’s stock, valued at approximately $191,000.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Daiwa SB Investments Ltd. grew its holdings in Zoetis by 92.0% during the 4th quarter. Daiwa SB Investments Ltd. now owns 18,152 shares of the company’s stock worth $1,308,000 after acquiring an additional 8,696 shares during the period. BLB&B Advisors LLC grew its holdings in Zoetis by 5.2% during the 4th quarter. BLB&B Advisors LLC now owns 50,460 shares of the company’s stock worth $3,635,000 after acquiring an additional 2,478 shares during the period. King Luther Capital Management Corp grew its holdings in Zoetis by 3.7% during the 3rd quarter. King Luther Capital Management Corp now owns 1,264,164 shares of the company’s stock worth $80,603,000 after acquiring an additional 44,697 shares during the period. California Public Employees Retirement System grew its holdings in Zoetis by 4.5% during the 3rd quarter. California Public Employees Retirement System now owns 1,295,752 shares of the company’s stock worth $82,617,000 after acquiring an additional 55,852 shares during the period. Finally, Columbus Circle Investors grew its holdings in Zoetis by 8.3% during the 3rd quarter. Columbus Circle Investors now owns 310,912 shares of the company’s stock worth $19,824,000 after acquiring an additional 23,785 shares during the period. 92.45% of the stock is owned by hedge funds and other institutional investors.
A number of analysts have commented on ZTS shares. Zacks Investment Research lowered shares of Zoetis from a “hold” rating to a “sell” rating and set a $83.00 target price for the company. in a report on Saturday, January 13th. Morgan Stanley raised shares of Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 target price for the company in a report on Wednesday, November 29th. Bank of America lifted their target price on shares of Zoetis from $80.00 to $87.00 and gave the stock a “buy” rating in a report on Friday, February 16th. Craig Hallum reaffirmed a “buy” rating and set a $85.00 target price (up previously from $77.00) on shares of Zoetis in a report on Tuesday, January 2nd. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $86.00 target price (up previously from $84.00) on shares of Zoetis in a report on Friday, February 16th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $80.28.
Zoetis Inc (NYSE ZTS) opened at $84.60 on Friday. The firm has a market cap of $40,931.15, a price-to-earnings ratio of 48.34, a PEG ratio of 1.89 and a beta of 0.97. Zoetis Inc has a 52-week low of $52.25 and a 52-week high of $85.54. The company has a current ratio of 3.85, a quick ratio of 2.55 and a debt-to-equity ratio of 2.77.
Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 15th. The company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.66 by $0.03. The business had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.40 billion. Zoetis had a net margin of 16.28% and a return on equity of 65.96%. The firm’s revenue was up 14.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.47 EPS. research analysts anticipate that Zoetis Inc will post 3.04 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, April 20th will be given a $0.126 dividend. The ex-dividend date of this dividend is Thursday, April 19th. This represents a $0.50 annualized dividend and a yield of 0.60%. Zoetis’s dividend payout ratio is currently 28.57%.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.